Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Giselle K Perez PhD"'
Autor:
Christina M Luberto PhD, Giselle K Perez PhD, Lucy Finkelstein-Fox PhD, Rachel A Millstein PhD, Lucy Fell BA, Emma Chad-Friedman MA, Elyse R Park PhD, MPH, Karen A Kuhlthau PhD
Publikováno v:
Global Advances in Health and Medicine, Vol 10 (2021)
Objective Parents of children with learning/attentional disabilities (LAD) and autism spectrum disorder (ASD) are at elevated risk for chronic stress. Types of stress and treatment needs differ between these parent groups. We adapted our evidence-bas
Externí odkaz:
https://doaj.org/article/971255b3819746a6b5195826f9da4d44
Autor:
Elyse R Park PhD, Christina M Luberto PhD, Emma Chad-Friedman, Lara Traeger, Daniel L Hall PhD, Giselle K Perez PhD, Brett Goshe PhD, Ana-Maria Vranceanu PhD, Margaret Baim MS, ANP-BC, John W Denninger MD, PhD, Gregory Fricchione MD, Herbert Benson MD, Suzanne C Lechner PhD
Publikováno v:
Global Advances in Health and Medicine, Vol 10 (2021)
Background There is heterogeneity in conceptualizations of resiliency, and there is, to date, no established theoretically driven resiliency assessment measure that aligns with a targeted resiliency intervention. We operationalize resiliency as one
Externí odkaz:
https://doaj.org/article/0fb878b3ddde405ea7d29b2360cd735c
Autor:
Daniel L Hall PhD, Rachel A Millstein PhD, MHS, Christina M Luberto PhD, Giselle K Perez PhD, Elyse R Park PhD, MPH
Publikováno v:
Global Advances in Health and Medicine, Vol 9 (2020)
The COVID-19 pandemic has resulted in unprecedented stress and uncertainty, particularly among vulnerable populations such as healthcare workers who are facing a multitude of current and looming economic and psychosocial stressors. As clinician-scien
Externí odkaz:
https://doaj.org/article/5f502f2ef04f42ee91ad57136beb11dc
Autor:
Giselle K. Perez PhD, Anjali R. Oberoi MD, MPH, Lucy Finkelstein-Fox PhD, Elyse R. Park PhD, MPH, Ryan D. Nipp MD, MPH, Beverly Moy MD, MPH
Publikováno v:
Cancer Control, Vol 30 (2023)
Introduction Cancer clinical trials represent the “gold standard” for advancing novel cancer therapies. Optimizing trial participation is critical to ensuring the generalizability of findings across patients, yet trial enrollment rates, particula
Externí odkaz:
https://doaj.org/article/db89dd2bf72146e59c6b7908834de829